Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.

For more information on HAELO (NCT06634420), please visit clinicaltrials.gov. About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program ...

About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia’s ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while ...

Citizens JMP maintained its Market Perform rating on Intellia Therapeutics (NASDAQ: NTLA) stock, currently trading at $8.96, following positive three-year follow-up data from the company’s Phase ...

The company recently announced the start of patient screening for a phase 3 trial, called HAELO, which will test a one-off 50mg dose of NTLA-2002 in around 60 HAE patients and is due to readout ...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...